Form 4: Avalo Therapeutics Insider Reports PSU Vesting

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, reported the vesting of performance stock units (PSUs) on May 21, 2026, with shares set to fully vest on August 19, 2028.

Summary

• Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., has filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the acquisition of 39,900 shares of Common Stock on May 21, 2026, with a transaction code indicating acquisition.
• These shares represent performance stock units (PSUs) granted on August 19, 2025, which contingent rights to receive one share of common stock upon achieving certain performance goals.
• The Compensation Committee of Avalo Therapeutics certified the achievement of these performance goals on May 21, 2026.
• The PSUs will fully vest on August 19, 2028, provided the reporting person remains in service until that date.
• Following this transaction, Mr. Sullivan beneficially owns 40,323 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating that performance targets have been met for a significant equity award, but the full benefit is deferred and contingent on continued employment.

Positives

• Achievement of performance goals for PSUs has been certified by the Compensation Committee.
• The reporting person, CFO Christopher Ryan Sullivan, has a significant stake in the company's future through the vesting of PSUs.
• The company's performance metrics have met the criteria set for PSU vesting.

Negatives

• The full vesting of the PSUs is contingent on continued service until August 19, 2028, indicating a potential risk of forfeiture if employment ceases before then.

Risks

• The reporting person's continued employment with Avalo Therapeutics through August 19, 2028, is a condition for the full vesting of the performance stock units.
• Failure to meet performance goals, although certified as met for this tranche, could impact future equity awards.

Future Outlook

The full vesting of 39,900 performance stock units is scheduled for August 19, 2028, contingent upon the reporting person's continued employment with the company.

Management Comments

• The Compensation Committee of the Issuer certified achievement of such performance goals.
• As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

Industry Context

StockSavvy.ai notes that this Form 4 filing by Avalo Therapeutics' CFO is a standard disclosure for insider equity awards. The vesting of performance stock units (PSUs) is a common incentive mechanism in the biotechnology sector, aligning executive compensation with company performance and long-term value creation.

Stakeholder Impact

• Shareholders: The vesting of PSUs aligns management's interests with long-term shareholder value, as performance goals have been met.
• Employees: This filing highlights the company's use of performance-based incentives, which can be a motivator for other employees.
• Management: The CFO's equity award is confirmed to be on track for vesting, reinforcing their commitment to the company.

Next Steps

• Continued service by Christopher Ryan Sullivan through August 19, 2028, to ensure full vesting of PSUs.
• Monitoring of Avalo Therapeutics' performance to ensure continued alignment with executive incentives.

Key Dates

Keywords

Form 4, Avalo Therapeutics, AVTX, Christopher Ryan Sullivan, Chief Financial Officer, Performance Stock Units, PSU, Vesting, Beneficial Ownership, SEC Filing, Insider Trading